Quantitative Investment Management LLC Buys New Position in IQVIA Holdings Inc. $IQV

Quantitative Investment Management LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,754 shares of the medical research company’s stock, valued at approximately $2,422,000.

A number of other large investors have also recently bought and sold shares of IQV. Brighton Jones LLC raised its holdings in shares of IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the last quarter. Empowered Funds LLC boosted its holdings in IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new position in IQVIA in the second quarter valued at $514,000. Wedbush Securities Inc. increased its stake in IQVIA by 10.7% in the 2nd quarter. Wedbush Securities Inc. now owns 1,608 shares of the medical research company’s stock valued at $253,000 after buying an additional 156 shares during the last quarter. Finally, Penserra Capital Management LLC lifted its position in IQVIA by 10.3% during the 2nd quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock worth $151,000 after buying an additional 90 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 5.3%

Shares of IQVIA stock opened at $162.45 on Friday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The business has a fifty day simple moving average of $202.79 and a two-hundred day simple moving average of $206.83. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The company has a market capitalization of $27.57 billion, a price-to-earnings ratio of 20.67, a P/E/G ratio of 1.66 and a beta of 1.39.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on IQV shares. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Mizuho set a $215.00 price target on IQVIA in a research report on Monday, February 23rd. Finally, Royal Bank Of Canada began coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $229.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.